[from left] Dr. Gege Gatt, CEO of EBO, Dr. Harietta Eleftherochorinou, Founding and Managing Partner at Olea Venture Partners and Dr. Lampros Kourtis, Managing Partner at Olea Venture Partners.
Olea Venture Partners (‘Olea’), a healthcare and life sciences investor, has completed an investment in EBO, a provider of AI-powered patient engagement solutions, to support the next phase of the company's growth.
The investment will accelerate adoption of EBO’s technology across health systems and healthcare providers, support expansion into new clinical and operational workflows, and fund further international expansion across Europe and into the United States.
Backed by the European Investment Fund and supported by EquiFund II, Olea combines growth capital with hands-on strategic and operational support, drawing on experience across AI, healthcare, science and commercialisation.
In a field still defined by promise, EBO is defined by proof,” said Dr. Harietta Eleftherochorinou, Founding and Managing Partner at Olea Venture Partners. “The company is already delivering measurable impact in some of the most complex healthcare environments, with patient adoption rates of up to 97%, significant operational capacity released for hospital teams and customer ROI of up to 5x.”
EBO’s AI technology automates complex patient interactions, including appointment management, self-assessments and pathway communications, delivering improved patient experiences and sustained operating savings. The platform operates as infrastructure inside regulated healthcare workflows, not as a standalone AI tool.
The company has established commercial operations in the UK, Italy, Greece and Malta, with 24 live deployments across UK NHS Trusts and hospitals.
“What stands out about EBO is that it solves a clear operational need with a platform built for healthcare and proven adoption across markets. The next phase is about scaling what already works.
Olea will support the EBO team as it deepens adoption across the UK, strengthens its Southeast European presence, and enters the United States with a particular focus on health-system partnerships, commercial strategy and building a repeatable model for international expansion.”
Dr. Gege Gatt, CEO and Founder of EBO, said, “This investment is a vote of confidence in EBO and in the scale of the opportunity ahead. With Olea, we have a partner who understands that healthcare innovation succeeds through trust, evidence and disciplined execution.”
“Together, we will help more healthcare organisations make patient access simpler, release capacity for their teams and adopt AI responsibly within the systems and safeguards they already rely on.”
The investment marks the next stage in EBO’s growth as the company scales a healthcare AI platform already deployed across multiple markets and clinical environments.
Access your guide to AI in healthcare
Discover how EBO can help your organisation create better experiences for patients and teams.
